Over the last three years, the FDA has approved six new hemophilia drugs ... between allowing our blood to stay slippery and smooth and flow, versus more of a clot.” In its annual Drugs to ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS and could allow patients to reduce the number of injections they need ...

Qfitlia is indicated in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. It is almost exclusively found ...

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow. Pfizer and Sangamo are hoping for a faster trajectory ...

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere ... with haemophilia B that isn't fully controlled justify its ...

Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting a price directly in ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix ... and “represents a step forward in evaluating cell and gene therapies in the UK.” ...

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the ...

Simon, Bugos and colleagues report the design and characterization of monospecific and bispecific synthetic chimeric T cell receptors, conferring increased antigen sensitivity and antitumor ...